Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis

Table 3 Sensitivity analyses according to various moderators

Moderator	N studies	Effect Sizes SMD^a	95% CIs	Heterogeneity I²	z-score	p value < =^b
Risk of Bias status
High	22	0.66	0.41–0.90	75.5	5.2	0.001
Low	1	0.84	0.62–1.1	0	7.4	0.001
Some	7	0.56	0.12–1.0	93.7	2.5	0.014
Blinding
Yes	3	0.96	0.30–1.62	77.4	2.9	0.041
No	27	0.61	0.39–0.82	85.3	5.4	0.001
Randomized
Yes	25	0.70	0.47–0.93	86.3	6.0	0.001
No	5	0.38	−0.09-0.85	63.4	1.58	0.11
Additional Treatment
Chemotherapy	7	0.41	0.05–0.76	89.3	2.2	0.025
No add. Treatment	4	0.77	0.20–1.34	64.6	2.6	0.008
Individual best care	1	2.33	1.93–3.38	0	5.2	0.001
Conventional	16	0.58	0.36–0.81	66.2	5.1	0.001
Surgery	2	0.62	0.40–0.83	0	5.5	0.001
Controls
Active	8	0.60	0.20–1.01	81.4	2.9	0.004
No active	22	0.65	0.41–0.90	85.9		0.001
Cancer type
Lung cancer	3	−0.18	−0.41–0.06	0	1.45	0.15
Breast cancer	10	0.48	0.29–0.68	50	4.83	0.00001
Product
Abnova V.	2	1.06	0.07–2.04	86.5	2.1	0.036
Eurixor	4	0.94	0.32–1.60	87.7	3.0	0.003
Helixor	3	0.35	0.13–0.57	0	3.1	0.002
Iscador	17	0.58	0.28–0.87	88.6	3.8	0.001
Lektinol	2	0.67	−0.13-1.48	63.4	1.6	0.1
Other	2	0.67	0.26–1.09	0	3.2	0.001
Country
Germany	19	0.64	0.38–0.90	80.5	4.8	0.001
Other	11	0.64	0.30–0.98	89.4	3.7	0.001
Sponsoring
Corporate	10	0.49	0.11–0.87	92.0	2.5	0.011
Public	3	0.64	−0.05–1.33	91.1	1.8	0.07
Mixed	10	0.73	0.36–1.1	35.2	3.8	0.001
No Information	7	0.73	0.27–1.19	82.8	3.1	0.002
Type of Measure
Index¹	6	0.33	−0.12-0.78	50.1	1.4	0.1
Scale²	14	0.71	0.41–1.0	90.9	4.6	0.001
Self Regulation³	10	0.73	0.39–1.07	35.2	4.1	0.001

ISSN: 2662-7671